Metabolic health
MOTS-c is explored for its role in how cells respond to metabolic stress and glucose availability.
Explore the research →MITOCHONDRIAL & METABOLIC RESEARCH
MOTS-c
Made naturally by mitochondria, MOTS-c has attracted attention for its possible role in energy, exercise performance, metabolism and healthy ageing.
Metabolic signallingExercise biologyMuscle function
Strong preclinical interest; no established human treatmentHuman work shows that endogenous MOTS-c responds to exercise, but administered MOTS-c has not yet established clinical efficacy or a validated therapeutic dose in people.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Why are people interested in MOTS-c?
MOTS-c attracts interest because it connects the body's cellular energy system with exercise, glucose handling and physical performance. That makes it particularly interesting around energy, metabolic health and the possibility of maintaining physical resilience as we get older.
Energy & exercise performance
Exercise-related changes in endogenous MOTS-c have made physical performance a major research theme.
Explore the research →Healthy ageing & resilience
MOTS-c is discussed around maintaining function with age rather than treating a defined ageing disease.
Explore the research →THE SCIENCE BIT
A message from the cell's energy system.
MOTS-c is a short peptide encoded within mitochondrial DNA. Research links it with metabolic stress responses, including AMPK-related signalling—the cell's response to changing energy demand.
In cell experiments, MOTS-c can move into the nucleus during stress and influence gene expression. Human exercise studies examine the naturally occurring peptide; they do not establish the effects of taking manufactured MOTS-c.
See the studies & trials →- Mitochondria
- Where the peptide is encoded
- AMPK-related signals
- Energy-stress responses
- Nucleus
- Stress-responsive gene expression
How this connects to the research
Mechanistic and animal findings; human treatment effects remain unestablished.
Read a primary source ↗FROM MOLECULE TO TISSUE
Where MOTS-c connects with the body
These are the tissues and biological systems behind the interest in MOTS-c.
- Skeletal muscle
- Exercise and glucose handling.
- Cell nucleus
- Experimental stress adaptation.
- Metabolic tissues
- Insulin-sensitivity research.
The research behind the interest
Metabolic health
MOTS-c attracts interest for the way it may help the body respond to changes in energy demand, blood sugar and metabolic stress.
Cell and animal studies link MOTS-c with AMPK-related signalling, insulin sensitivity and metabolic adaptation.
Strong preclinical evidenceExplore the studies →Energy & exercise performance
Energy, stamina and exercise capacity are among the biggest reasons people are interested in MOTS-c, particularly because the body appears to produce more of it in response to exercise.
A 2021 study reported exercise-responsive MOTS-c in human skeletal muscle while administered peptide improved performance mainly in mouse models.
Human biomarker + preclinical evidenceExplore the studies →Muscle function
MOTS-c is closely linked with skeletal muscle, leading to interest around how muscles use energy, adapt to exercise and cope with physical stress.
Experimental work explores glucose uptake, mitochondrial-nuclear communication and stress adaptation in muscle.
Mechanistic & preclinical evidenceExplore the studies →Healthy ageing & resilience
Healthy-ageing interest centres on maintaining energy, movement and physical capacity as we get older rather than treating one particular age-related condition.
Late-life treatment improved physical capacity and healthspan measures in mice; clinical translation remains unproven.
Promising preclinical evidenceExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableMOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance ↗
Cell systems and mouse metabolic models
MOTS-c altered folate and purine metabolism and activated AMPK-related signalling.
Treatment prevented diet-induced obesity and insulin resistance in mouse models.
MOTS-c as an exercise-induced regulator of physical decline and muscle homeostasis ↗
Human exercise sampling plus young, middle-aged and old mice
Endogenous MOTS-c increased in human skeletal muscle and circulation after exercise.
Administered peptide improved physical performance in mice; this was not a human treatment trial.
The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress ↗
Human cell systems exposed to glucose restriction and metabolic stress
MOTS-c moved into the nucleus following metabolic stress in an AMPK-dependent manner.
The study linked MOTS-c with stress-responsive nuclear gene expression; it did not test a treatment outcome in people.
Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes ↗
Human type 2 diabetes samples, isolated mouse islets and several mouse diabetes/senescence models
Circulating MOTS-c was lower in the sampled type 2 diabetes group, although the groups also differed substantially in age.
Administered MOTS-c reduced senescence-related signals and improved glucose outcomes in mouse models; this was not a human treatment trial.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceEarly
1/5 evidence depth
Human evidence is observational or biomarker-based rather than an intervention trial of MOTS-c.
✓
Clinical efficacyEarly
1/5 evidence depth
No controlled human efficacy trial has established a therapeutic benefit.
◇
Safety evidenceEarly
1/5 evidence depth
Long-term safety, pharmacokinetics and dose-response in humans remain insufficiently characterised.
⌁
Preclinical evidenceStrong
4/5 evidence depth
Multiple cell and animal studies support metabolic-stress and muscle-related mechanisms.
HOW TO READ THESE SCORESStrong preclinical evidence · early human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
HOW THE MOTS-C EVIDENCE CONNECTS
A promising signal with one major step still missing
The biological story is coherent, but each stage below represents a different level of evidence. They should not be treated as interchangeable.
Endogenous signal
MOTS-c exists naturally and changes with exercise.
Observed in humansCell pathways
Metabolic-stress and AMPK-related signalling are mapped.
Mechanistic evidencePhysical capacity
Administered peptide improved performance in mouse models.
Preclinical signalClinical benefit
Controlled human treatment outcomes are still needed.
Not establishedWhat would move the evidence forward?Controlled human trials that test administered MOTS-c against meaningful metabolic or physical-function outcomes.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with MOTS-c
Community interest centres on energy, exercise capacity, body composition, metabolic health and maintaining physical resilience with age. These goals have a genuine biological research story behind them, while the effects of administered MOTS-c in people remain untested.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Training capacity and less perceived fatigue
Fitness interest centres on getting through sessions, maintaining effort and recovering from activity. The mitochondrial-peptide story makes these goals attractive, while much of the treatment evidence remains experimental.
- What makes a report informative
- Performance and recovery under comparable conditions.
- What can muddy the picture
- Fitness gains from training and other compounds can dominate the account.
Metabolic health and weight-related goals
People are interested in glucose handling, a smaller waist or feeling metabolically healthier. These overlap with diet and weight-loss treatment goals but are not interchangeable outcomes.
- What makes a report informative
- Waist trends and relevant measured metabolic outcomes.
- What can muddy the picture
- A leaner appearance does not prove improved insulin sensitivity.
Resilience as activity gets harder with age
The attraction is maintaining physical capability rather than accepting gradual decline. Natural MOTS-c levels and exercise biology help explain interest but do not establish benefit from manufactured peptide.
- What makes a report informative
- Everyday function and exercise tolerance over time.
- What can muddy the picture
- Human biomarker associations are different from controlled treatment trials.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
Energy and training capacity
People commonly explore MOTS-c in the hope of steadier energy, better training tolerance or an easier return to exercise. Reports are difficult to separate from changes in sleep, diet and training load.
Human findings & limits
Human studies show exercise-related changes in naturally produced MOTS-c, not proven benefit from injected peptide.
Laboratory & animal context
Mouse studies report improved physical capacity and metabolic adaptation after administered MOTS-c.
What this means: One of the clearest reasons for interest, supported by human exercise biology and animal treatment data—but not yet a demonstrated performance treatment in people.
Metabolic health
Glucose handling, insulin sensitivity and day-to-day metabolic resilience are recurring themes, particularly among people already changing diet or activity.
Human findings & limits
Observational work has linked lower endogenous MOTS-c with some metabolic conditions, but cannot show that taking MOTS-c improves them.
Laboratory & animal context
Diet-induced obesity, insulin-resistance and pancreatic-islet models show positive metabolic signals.
What this means: A substantial preclinical theme that still needs a controlled human intervention study.
Body composition and weight management
Some users discuss MOTS-c alongside calorie control, resistance training or GLP-1 medicines, usually expecting indirect help through energy or metabolic function rather than appetite suppression.
Human findings & limits
No controlled human study has shown weight loss or improved body composition from administered MOTS-c.
Laboratory & animal context
The original mouse work reported protection against diet-induced obesity and insulin resistance.
What this means: The community goal is understandable from the animal data, but a human weight-management effect has not been established.
Healthy ageing and resilience
Longevity communities focus on maintaining movement, exercise capacity and metabolic flexibility rather than treating one defined ageing disease.
Human findings & limits
No trial has shown longer life or improved healthspan from MOTS-c administration in people.
Laboratory & animal context
Late-life mouse experiments reported improved physical function and several healthspan measures.
What this means: A compelling ageing-biology research lead, not an established longevity intervention.
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
ILLUSTRATIVE COMMUNITY PATTERN
ANECDOTAL · UNVALIDATEDHow a lower start, step-up and break are often described
This visual summarises a commonly published editorial/community pattern. It is not taken from a native MOTS-c human trial, is not an official schedule and should not be read as a recommendation.
1Weeks 1–2
5 mg · once weeklyEditorial starting pattern
2Weeks 3–8
5 mg · up to twice weeklyOptional step-up described by the source
3Weeks 9–12
Continue or stopEditorial cycle window varies
4After cycle
4–8 week breakCommonly discussed pause
What people reportA recurring editorial pattern describes 5 mg once weekly for two weeks, with an optional increase to twice weekly, usually within an eight-to-twelve-week cycle.
What is not establishedThere is no validated human dose, titration rule, treatment course, maintenance schedule or evidence-based break interval for administered MOTS-c.
COMMUNITY / EDITORIAL CONTEXT
The example is compiled from specialist editorial guidance and recurring community protocols. It describes reported practice, not a clinically tested human schedule.
HUMAN DOSING EVIDENCE
No validated human therapeutic dose or cycle has been established. Research and evidence details remain available in the Research tab.
No validated human MOTS-c treatment dose, titration schedule or maintenance protocol has been established.
No structured human dosing protocol has been added for this compound. That should not be interpreted as evidence for a community dosing schedule.
COMMUNITY DISCUSSION
Editorial/community protocol · no validated human doseWhat people commonly discuss
STARTING APPROACHES
A commonly published editorial pattern uses 5 mg once weekly for the first two weeks, with an optional increase to 5 mg twice weekly after assessing tolerance.
DURATION / CYCLES
Editorial and community protocols commonly use eight-to-twelve-week cycles; this has not been validated in a native MOTS-c human trial.
MAINTENANCE DISCUSSION
A four-to-eight-week break is described between cycles; no evidence-based maintenance or washout interval exists.
Community patterns are anecdotal and unvalidated unless a linked human study independently supports the same approach.
COMMUNITY-REPORTED PRACTICEInjection patterns people commonly discussPopular uses · route · site discussion · timing · durationMixed anecdotal consensus
Exercise capacityEnergyMetabolic healthHealthy ageing
ROUTE PEOPLE DISCUSS
Subcutaneous injection is the route most often discussed online.
INJECTION-SITE DISCUSSION
General subcutaneous sites are discussed; there is no evidence that a specific site improves MOTS-c outcomes.
TIMING PEOPLE DISCUSS
Morning or pre-exercise timing is commonly discussed, without human comparative evidence.
DURATION / CYCLE DISCUSSION
Eight-to-twelve-week cycles with a four-to-eight-week break recur in editorial and community protocols, although patterns vary.
What the evidence supports
No controlled human study has established route, amount, frequency, timing, cycle length or break schedule for administered MOTS-c.
Community reports describe what people say they do; they are not instructions, validated protocols, or evidence that a particular injection site or timing improves outcomes.CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
Daily editorial example
Community example · not clinically validatedThis is a separate daily description from the weekly community pattern on the dosage page. Neither is an established human MOTS-c regimen. Human studies of naturally occurring MOTS-c do not validate injected doses.
Form and route: Injection under the skin, as described in the example
| Calendar stage | Amount each time |
|---|---|
| Weeks 1–2 | 0.2 mg |
| Weeks 3–4 | 0.4 mg |
| Weeks 5–6 | 0.6 mg |
| Weeks 7–8 | 0.8 mg |
| Weeks 9–10 | 1 mg |
Frequency: Every day · 1 entry per scheduled day.
This copy stops at ten weeks; the open-ended final stage in the editorial description is not continued automatically.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Often combined with
OFTEN COMBINED WITH
Community rationale · component roles · evidence boundaryWhy people explore pairings with MOTS-c
See the thinking behind community-named stacks, the different role each component is proposed to play, and how much of that idea has actually been tested as a combination.
Potential first, evidence in context. Pairings are usually explored because their research stories appear complementary. That makes them interesting to study, but does not yet prove extra benefit or safety.
CURRENT COMPOUNDMOTS-c
→
OFTEN EXPLORED WITHMOTS-c + NAD+ precursors
MOTS-c + NAD+ / NR / NMN
→
OFTEN EXPLORED WITHMOTS-c + exercise programme
MOTS-c + Structured exercise
→
OFTEN EXPLORED WITHMOTS-c + SS-31
MOTS-c + SS-31 / elamipretide
Combination-specific human research is the strongest evidence for what a pairing adds. Evidence for either ingredient alone should not be silently transferred to the combination.
MMOTS-C IS USUALLY DISCUSSED AROUNDMetabolic stress signalling and exercise capacity
＋Community interest follows its mitochondrial origin, exercise response and the physical-capacity signals reported in mice.
PTHE PAIRED APPROACH MAY ADDEnergy support, training stimulus or another mitochondrial angle
The proposed roles differ across NAD+ precursors, structured exercise and SS-31; none proves that combining them improves results.
＋
OFTEN EXPLORED WITH
Explore →＋MOTS-c + NAD+ precursors
MOTS-c + NAD+ / NR / NMNWHY IT IS EXPLOREDExplored around complementary mitochondrial and cellular-energy themes.
Biological rationale only; combination-specific human efficacy is untested.OFTEN EXPLORED WITH
Explore →＋MOTS-c + exercise programme
MOTS-c + Structured exerciseWHY IT IS EXPLOREDInterest follows the finding that endogenous MOTS-c responds to exercise.
Exercise has established benefits; injected MOTS-c has not been shown to add to them in humans.OFTEN EXPLORED WITH
Explore →MOTS-c + SS-31
MOTS-c + SS-31 / elamipretideWHY IT IS EXPLOREDDiscussed as two different mitochondrial research angles: stress signalling and mitochondrial membrane bioenergetics.
Community and mechanistic rationale only; no controlled human trial has tested the combination.01Why it appeals
People aim to combine different parts of the energy, metabolism and exercise story.
02What is genuinely known
Exercise has established benefits; MOTS-c has human biomarker data and mainly preclinical treatment data.
03What remains untested
No controlled human trial has established that these MOTS-c pairings add efficacy or remain safe together.
Safety context
SAFETY & UNCERTAINTY
What is known—and what still needs defining
01ENCOURAGING CONTEXTMOTS-c is naturally produced
Its endogenous role and exercise-responsive behaviour in people provide a real biological basis for continued research.
02THE IMPORTANT DISTINCTIONTaking it is not the same as producing it
Manufactured, administered MOTS-c still needs human dose-response, tolerability, interaction and longer-term safety research.
What the current evidence saysMOTS-c is naturally produced in the body and has an established experimental biology. That is encouraging context, but it does not yet provide a human safety profile for a manufactured, administered product. Dose-response, immune reactions, interactions and longer-term effects remain uncertain.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Human studies represented here measure naturally occurring MOTS-c; they do not establish the safety of repeated injections.
Injection-site discomfort, headache and fatigue appear in online reports, but frequency and causality remain unknown.
Product quality, contamination, concentration and injection practice can introduce risks separate from the peptide itself.
Why this matters
Online reports sometimes mention transient injection-site discomfort, headache or fatigue. These reports are useful signals to notice, but their frequency, cause and relationship to dose have not been established in controlled research.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
11 sourcesSources used on this profile
Original publicationMOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistanceJournal / DOI ↗Bibliographic recordMOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistancePubMed ↗Original publicationMOTS-c as an exercise-induced regulator of physical decline and muscle homeostasisJournal / DOI ↗Bibliographic recordMOTS-c as an exercise-induced regulator of physical decline and muscle homeostasisPubMed ↗Original researchThe mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stressFree full paper ↗Bibliographic recordThe mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stressPubMed ↗Original researchMitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetesNature · full paper ↗Original researchSafety and uncertainty2015 metabolic-homeostasis study ↗Professional sourceUnited KingdomMHRA products database ↗Professional sourceUnited StatesFDA Drugs@FDA database ↗Professional sourceSportWADA Prohibited List ↗
CURRENT STATUS
How to interpret its position today
No UK-authorised medicine is represented on this profile
MOTS-c is presented as a research compound. The MHRA products database should be checked for any future change in authorised status.
MHRA products database ↗No FDA-approved therapeutic product identified
Regulatory evaluation of a substance for compounding is separate from approval of a drug for safety and efficacy.
FDA Drugs@FDA database ↗Prohibited status should be checked
Competitive athletes should check the current WADA Prohibited List before exposure to experimental metabolic modulators.
WADA Prohibited List ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.